Anthos Therapeutics

Anthos’ ABP-959 outperforms Xarelto in preventing bleeding events in phase 2 trial

Blackstone Life Sciences’ substantial $250 million investment in an ex-Novartis drug candidate has yielded yet another positive outcome in its ...